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Abstract
Serotonergic involvement has been implicated in preferential consumption of treat foods. We tested
the effect of acute tryptophan depletion (ATD) on food consumption by overweight and lean adults
with and without a history of recurrent major depressive disorder (MDD). ATD and taste-matched
placebo challenges were administered double-blind in counter-balanced order. Participants were
classified as lean (n = 36) or overweight (n=19) on the basis of body mass index (BMI). Total calorie,
carbohydrate, protein, and sweet food consumption were assessed via a test meal 8-hours following
ATD. Four food items of comparable palatability were offered as a part of the test: two sweet (one
carbohydrate-rich, and one protein-rich) and two non-sweet (one carbohydrate-rich, and one protein-
rich). As compared to the placebo challenge, ATD significantly increased sweet calorie intake among
overweight participants and increased their propensity to consume sweet food first before any other
type of food. Lean participants’ sweet calorie intake and food preference were unaffected by ATD.
Findings suggest serotonergic involvement in the sweet food consumption by overweight individuals.
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1. Introduction
Obesity, defined as a body mass index of 30 or greater, is a significant public health threat in
the US, with 31% of the population affected (Flegal, Carroll, Ogden, & Johnson, 2002; Hedley
et al., 2004). The growing obesity epidemic has been attributed to an environment where high-
calorie, palatable foods are increasingly plentiful and easily accessible (Wadden, Brownell, &
Foster, 2002). However, not all humans who are exposed to an abundance of highly palatable
foods overeat or become overweight. Neurobiological variations may influence vulnerability
towards overconsumption and weight dysregulation (Levitan et al., 2004).
Variation in brain serotonergic activity (5-hydroxytryptophan, 5-HT) has been implicated in
appetite regulation and impulse control. Serotonin inhibits neuropeptide Y, resulting in
suppression of hunger and food intake (Halford & Blundell, 2000). A chronic hyposerotonergic
state could result in a prolonged pattern of compulsive overeating, ultimately contributing to
obesity. Supporting the role of 5-HT in weight regulation are data showing that stimulation of
postsynaptic 5-HT receptors inhibits carbohydrate consumption in rats (Leibowitz, Weiss, &
Shor-Posner, 1987; Shor-Posner, Grinker, Marinescu, Brown, & Leibowitz, 1986), with more
vigorous stimulation reducing total calorie intake. Conversely, a low brain 5-HT level is
associated with enhanced appetite (Leibowitz et al., 1987) and impaired impulse control in rats
(Bizot, Le Bihan, Puech, Hamon, & Thiebot, 1999) and in humans at risk for alcoholism
(Crean, Richards, & de Wit, 2002; LeMarquand, Benkelfat, Pihl, Palmour, & Young, 1999).
Among obese humans, many medications that enhance serotonergic function induce weight
loss (Hanotin, Thomas, Jones, Leutenegger, & Drouin, 1998; Pijl et al., 1991; Strain, Strain,
& Zumoff, 1985; Toornvliet, Pijl, Hopman, Westendorp, & Meinders, 1997; Wadden et al.,
2005), and reduce caloric intake (McTavish & Heel, 1992; Pijl et al., 1991; Wurtman et al.,
1981) (although it should be noted that some serotonergic agents with prominent
anticholinergic and antihistaminic action cause weight gain) (Ruetsch, Viala, Bardou, Martin,
& Vacheron, 2005). Whether 5-HT plays a role in inhibitory control of eating in overweight
individuals, specifically, has not been well studied.
ATD is a procedure that acutely and transiently reduces 5-HT synthesis. By 5–7 hours
following depletion, brain 5HT synthesis is reduced by 85–90%, and depressive symptoms
increase in those vulnerable to MDD (Hood, Bell, & Nutt, 2005). Most research using ATD
methodology has examined affective changes among those vulnerable to affect dysregulation
(Delgado et al., 1994; Leyton et al., 1997; Neumeister et al., 2004; Smith, Fairburn, & Cowen,
1997; Spring et al., 2007). The effect of lowering brain 5-HT synthesis on eating behavior has
been much less well characterized, and one possibility is that ATD-induced negative mood is
a predisposing factor for emotionally-driven eating.
Most existing research has been confined to examining ATD effects on disordered eating and
cognition among bulimics. In bulimia, ATD has been found to engender increased desire to
binge (Kaye et al., 2000), fear of losing control over eating (Smith, Fairburn, & Cowen,
1999; Weltzin, Fernstrom, Fernstrom, Neuberger, & Kaye, 1995), and weight concern (Smith
et al., 1999). Findings are mixed, however, on the effect of ATD on caloric intake and binge
eating (Kaye et al., 2000; Oldman, Walsh, Salkovskis, Fairburn, & Cowen, 1995; Weltzin et
al., 1995). In some studies bulimics have increased palatable food intake following ATD
(Smith et al., 1999; Weltzin et al., 1995), whereas in others no change in intake was observed
(Kaye et al., 2000; Oldman et al., 1995). Small samples and varying methodology may account
for mixed findings (Kaye et al., 2000). Because most of these studies recruited lean participants,
few data characterize 5-HT effects on the food consumption of overweight people who do not
have an eating disorder.
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The present study is the first to test the hypothesis that greater body mass index (BMI) is
associated with disproportionately increased food consumption following ATD. Debate exists
about whether brain 5-HT has a generic influence on overall intake, or whether it selectively
influences intake of carbohydrates, sweets, or palatable “comfort” foods (Asin, Davis, &
Bednarz, 1992; Spring, Chiodo, & Bowen, 1987; Wogar, Bradshaw, & Szabadi, 1991). To
evaluate that question, total energy consumption, carbohydrate-rich food consumption, and
sweet food consumption were each assessed. The carbohydrate hypothesis predicted that ATD,
relative to placebo, would increase consumption of carbohydrate-rich foods. The sweetness
hypothesis, predicted that ATD, relative to placebo, would increase consumption of sweet
tasting foods. We also tested the prediction that each hypothesized effect would occur
disproportionately among overweight participants.
2. Methods and Materials
2.1 Participants and Study Design
Participants (N=55) in the current study were part of a larger study that examined the effects
of ATD on dysphoric mood in smokers and never-smokers with and without a personal and
family history of DSM-IV major depression (Spring et al., 2007). A complete description of
study design and methods are reported elsewhere (Spring et al., 2007). Candidates were
excluded from participation if they were pregnant or lactating, had food allergies, were
receiving smoking treatment including nicotine replacement, had received substance abuse
treatment within the past year, or were taking psychotropic medications or medications known
to influence mood or appetite. Participants with eating disorders, current depression, or other
psychiatric illness also were excluded. Finally, participants were excluded for BMI ≥ 35 (Class
II or higher obesity) or unstable medical condition (e.g., diabetes). The study was approved by
local institutional review boards. Participants were compensated $100.00.
2.2 Measures
Body Mass Index (BMI)—Body mass index was measured by weight and height using self
report. BMI was calculated by (weight in pounds/(height in inches)2) × 704.5. Participants with
BMI of 19–24.9 or less were classified as lean, and those 25 to 34.9 were classified as
overweight.
Palatability Scale—The palatability scale assessed liking for 70 total food items. Food items
consisted of sweet and non-sweet foods presented in random order. Items were drawn from a
large pool of foods previously rated as palatable by a normative sample (Spring, Pagoto,
McChargue, Hedeker, & Werth, 2003). Participants were asked to rate how much they liked
each food on a 1–10 point scale. Higher responses indicated greater palatability.
2.3 Procedures
Experimental session—Participants were given the ATD and placebo challenge drinks on
different test days separated by one week. Mixtures were administered double-blind and in
counterbalanced order. Female participants completed the study between days 7 and 21 of their
menstrual cycle. Smokers within each BMI group (58% of each) smoked at hourly intervals
during the test sessions to prevent nicotine withdrawal. On each test day, participants arrived
by 8:00 a.m. after a 12-hour fast. Ad libitum intake preceded the 12-hour fast because dietary
restrictions for more than 12 hours preceding ATD do not appear to be necessary to produce
significant reduction in plasma tryptophan.(Spring et al., 2007) Participants underwent baseline
testing of mood (Hamilton Depression Rating Scale (Hamilton, 1960) and blood collection
through venipuncture to assess plasma amino acid levels (see Table 1 for experimental session
timeline). At 9:30 a.m., participants ingested one of two calorie-matched beverages. The ATD
mixture consisted of the following 15 amino acids (102.5 total g): l-alanine (5.5g), l-arginine
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(4.9g), l-cystine (2.7g), glycine (3.2g) l-histidine (3.2g), l-isoleucine (8.0g), l-leucine (13.5g),
l-lysine monohydrochloride (11.0g), l-methionine (3.0g), l-phenylalanine (5.7g), l-proline
(12.2g), l-serine (6.9g), l-threonine (6.9g), l-tyrosine (6.9g), and l-valine (8.9g). Three amino
acids, methionine, cystine, and arginine, were encapsulated because their unpalatable taste
could not be masked by chocolate and peppermint. The remaining amino acids were mixed
with 3 oz. of tonic water and blended with crushed ice, chocolate syrup, and peppermint extract.
The capsules were ingested approximately 15 minutes prior to the drink. In the placebo
condition, participants ingested capsules containing confectioner’s sugar, followed 15 minutes
later by a mixture consisting of 3 oz. of tonic water blended with crushed ice, chocolate syrup,
and peppermint extract. Baking soda and psyllium were also added to the placebo beverage in
order to mimic the granular, salty taste of the amino acid mixture.
All breakfast, lunch and snack foods were provided to participants on test days. The foods
served comprised the low-tryptophan diet used elsewhere (i.e.,(Delgado et al., 1990)).
Breakfast consisted of puffed rice, peaches, nondairy creamer, Knox gelatin and sugar. Lunch
was graham crackers, cream cheese, boiled potatoes and butter, green beans and Knox gelatin.
The mid-day snack consisted of four low-protein cookies and Kool-Aid. When not participating
in experimental procedures, each participant sat alone in a private room in which he or she
could watch videos or read magazines of emotionally neutral content.
At 5-hours post-challenge (2:30 p.m.), which marked the estimated onset of maximal
tryptophan depletion (range 5–7 hours;(Delgado et al., 1990)), participants underwent a 3-
minute guided imagery negative mood induction procedure. Seated in a reclining chair in a
soundproof room, each participant listened to a tape of a negative event script. Scripts were
equated between conditions on vividness and emotional valence (anxious, angry, sadness).
Participants were encouraged to sit back, close their eyes, and visualize the event as vividly as
possible. Negative autobiographical imagery was used to establish a depression-related
cognitive set that would allow the biological state produced by ATD to be experienced and
interpreted as genuine dysphoria. Blood sampling was then repeated to allow an assessment
of change in amino acid levels.
After the 8-hour assessment period, participants were served the dinner test meal. Based on
each participant’s palatability ratings, four food items of comparable palatability were offered:
two sweet (one carbohydrate-rich, and one protein-rich) and two non-sweet (one carbohydrate-
rich, and one protein-rich).1 A carbohydrate-rich food was defined as having a carbohydrate
to protein ratio of 6:1 or greater. A protein-rich food was defined as having a carbohydrate to
protein ratio less than 6:1. To ensure that all food items were comparable on palatability, only
those with palatability of 9 or 10 were selected (see Table 2 for sample foods and
classifications). Most items were prepackaged foods (i.e., frozen pizza, French fries, string
cheese, candy bars, fruit ice cups). Other items such as baked chicken, nuts, gummy bears, and
chocolate pudding were pre-portioned by the study dietician. Two servings of each food item
were pre-weighed and served. The order in which participants consumed each item was
recorded by a research assistant. Leftovers were weighed, from which total grams consumed
was calculated. Consumption in grams was later converted to calories for the analyses. Twenty
participants from the parent study sample of 75 were not included in this study because, due
to a miscoded food item, they inadvertently received food from only 3 of the 4 food categories.
At the end of the session, participants were given a high protein drink (Sustical) and instructed
to consume it the following morning.
2.4 Statistical Analysis
Preliminary analyses compared lean and overweight participants on demographic
characteristics, nausea in response to amino acid and placebo challenges, and changes in plasma
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amino acids from baseline to 5 hours. The dependent variable for the primary analysis of
consumption was operationalized in two ways (calorie intake and first choice food).
Calorie intake model—The first model evaluated total calorie intake. Square root
transformations were performed to normalize calorie data, which was positively skewed. A
multivariate analysis of variance (MANOVA) for repeated measures was implemented with
depression history (positive, negative) and BMI (lean, overweight) as between-subjects factors
and condition (placebo, ATD), sweetness (sweet, non-sweet), and food type (carbohydrate-
rich/protein-poor versus protein-rich/carbohydrate poor) as within-subjects factors. Gender,
smoking status (non-smoker, smoker), depressive symptom (HAMD) response to ATD
challenge, and condition order (ATD challenge first, placebo first) were entered as covariates.
First choice—The sequence in which the participant chose to consume foods was also
measured. The item that a participant elected to consume first was conceptualized as the most
immediately desired food. Two mixed effects logistic regression models estimated the
frequencies of first choices under placebo and ATD conditions as a function of BMI group
(overweight, lean). The outcome variable was dichotomous. First choice was equal to 0 for
protein and 1 for carbohydrate in the first model, and then first choice was equal to 0 for non-
sweet and 1 for sweet in the second model.
3. Results
3.1 Participant Characteristics
Participants (N=55) were 55% female and had a mean age of 33.19 years (SD=10.85). The
sample was 62% Caucasian, 24% African-American, 12% other, and 2% unknown. BMI
ranged from 18.64 to 32.39. Thirty-six participants were lean (BMI between 18.5 and 24.9)
and 19 were overweight (BMI between 30 and 34.9). Mean BMI was 21.82 (sd = 1.67) for
participants in the lean group (BMI < 25) and 27.75 (sd=1.95) for participants in the overweight
group. A total of 30 participants were smokers (21.8 ± 10.4 cigarettes per day, 18.4 ± 11.2
years). Almost half of participants (n=25; 45%) had a history of MDD, because individuals
with a history of MDD were selectively recruited for the parent study where history of MDD
was an independent variable.
Table 3 displays demographic characteristics of lean and overweight participants. No
differences were observed between lean and overweight participants on demographic variables,
MDD history, or smoking status. The ATD mixture did not appear to cause significant nausea,
as evidenced by the lack of difference in Visual Analogue Scale scores of nausea between
baseline and 5 hours (p = .50). Scores were 6.9 ± 13.4 at baseline and 10.2±20.0 at 5-hours.
The possible range of values was 0–100. No differences were observed between low and high
BMI groups in either condition in Visual Analogue Scale scores of hunger between baseline
and 5 hours [PBO: t(48)=.108, p=.914; AA: t(49)=−.323, p=.748]. Further, no differences were
observed between low and high BMI groups in either condition on change in tryptophan [PBO:
t(32)=−1.148, p=.260; AA: t(32)=.344, p=.733] or the ratio of tryptophan to other LNAAs
[PBO: t(32)=1.492, p=.145; AA: t(32)=.055, p=.956].
3.2 Caloric Intake
The repeated measures MANOVA for total calorie intake revealed no significant interaction
of condition by BMI, F(1,46)=.40, p =.52, indicating that the effect of ATD on caloric
consumption did not differ between lean and overweight participants. The carbohydrate
hypothesis, which suggested that ATD would affect carbohydrate consumption, was not
supported, F(1,46) = .32, p =.86. The three-way interaction of condition by food type by BMI
was also not significant, F(1,46) = .41, p =.52.
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The sweetness hypothesis, which suggested that ATD would affect sweet calorie consumption
was supported by a significant condition by sweetness interaction, F(1,46) = 6.90, p =.01.
Participants consumed on average 10.78 calories more of sweets during ATD compared to
placebo. They also consumed 28.71 calories more of non-sweets during ATD compared to
placebo. BMI moderated this effect, as revealed by a significant interaction between BMI and
condition and sweetness, F(1,46) = 7.23, p =.01. This significant interaction was followed by
post-hoc paired comparisons, which were not significant for lean participants, t(33) = .99, p
= .32, but significant for overweight participants, t(18) = −2.37, p = .02. Overweight
participants increased their sweet intake in ATD compared to placebo by an average of 91
calories (see Figure 1). Although statistically non-significant, lean participants decreased their
sweet intake by an average of 32 calories. Non-sweet intake increased slightly for both
overweight and lean participants by an average of 16.97 and 36.82 calories, respectively, in
ATD. The significant interaction between BMI, ATD, and sweetness persisted when gender
and MDD history were included in the model. Table 4 shows the mean consumption of total
calories, carbohydrate/protein calories and sweet/non-sweet calories across the two conditions.
We also evaluated whether the effect of ATD on sweet food consumption persisted after
adjusting for ATD associated differences in depressive symptoms. This was defined as the
HAMD score at 7 hours on the ATD day subtracted from the HDRS score at 7 hours on the
placebo day. This variable was entered into the calorie intake model as a covariate. Results
showed that the difference between conditions in depressive symptom score at 7 hours had no
effect on calorie intake and was thus removed from the model.
First Choice—In the carbohydrate model, condition did not significantly interact with body
mass index (z =.60, p = .54). In the sweet model, BMI and condition significantly interacted
(z = 2.15, p = 01). Among lean participants, ATD diminished the odds of sweet being selected
as first choice. Among overweight participants, ATD increased the odds of a sweet being
selected as first choice (See Figure 2).
4. Discussion
Our study is the first to reveal a differential intake among overweight as compared to lean
individuals in response to ATD. Overweight participants increased their sweet calorie intake
in response to ATD relative to placebo. Lean individuals actually tended to decrease their sweet
calorie intake in response to ATD. On average, overweight participants consumed 123 more
calories of sweet-tasting food than their lean counterparts. We also found that overweight
participants responded to ATD by choosing to eat sweet foods first, before consuming non-
sweet foods. In contrast, lean participants responded to ATD in the opposite manner, that is,
they choose to eat non-sweet foods first. These effects on sweet food calorie intake and
preference persisted after adjusted for gender, MDD history, and any ATD associated
depressive symptoms.
Results of the present study suggest that acutely lowering 5-HT has a selective influence on
sweet food consumption. The present findings are consistent with previous research that links
sweet, palatable food intake to 5-HT deficiency (Asin et al., 1992; Wogar et al., 1991). At first
glance, results appear to be at variance with prior studies showing that indirect serotonergic
agonists selectively reduce elevated intake of carbohydrates, independent of sweetness
(Wurtman et al., 1993; Wurtman et al., 1981). However, since the high-carbohydrate snack
foods often overconsumed by overweight dysphoric adults also tend to be sweet (Drewnowski,
Kurth, Holden-Wiltse, & Saari, 1992), the discrepancy may be more apparent than real.
The behavioral pattern of reacting to 5-HT deficiency and emotional distress by increasing
sweets intake resembles the clinical profile in atypical depression, which is often accompanied
Pagoto et al. Page 6
Eat Behav. Author manuscript; available in PMC 2010 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
by overweight (Paykel, Parker, Rowan, Rao, & Taylor, 1983). Binge eating is at the extreme
end on a continuum of emotionally-triggered eating that can vary considerably in frequency
and energy content. In some overweight and obese individuals the 5-HT neuronal system may
be dysregulated, similar to what is observed in bulimics (Kaye et al., 2000). Jimerson and
colleagues propose that binge eating increases the plasma tryptophan to large neutral amino
acid ratio, increasing brain tryptophan availability and enhancing 5-HT synthesis (Jimerson,
Lesem, Kaye, & Brewerton, 1992). The current findings raise the prospect that serotonin plays
a role in the overeating patterns of overweight and obese individuals similar to its involvement
in bulimic binge eating.
Intake of sweets has also been shown to release mesolimbic dopamine (DA) in nonhumans
(Avena & Hoebel, 2003; Salamone, Cousins, McCullough, Carriero, & Berkowitz, 1994), not
unlike drugs of abuse. Serotonin neurons, in turn, inhibit mesolimbic DA neurons (Alex &
Pehek, 2007; Rothman & Baumann, 2006). Reduced 5-HT synthesis via ATD has been shown
to diminish serotonergic inhibitory control of the dopaminergic system which stimulates DA
release, craving, and compulsive drug-seeking (Cox et al., 2006). Possibly, via an indirect effect
on DA release, ATD may both heighten the incentive salience of sweet foods (Robinson &
Berridge, 1993, 2000; Roiser et al., 2006) and undermine control of the impulse to respond to
rewarding treats (Olausson, Engel, & Soderpalm, 2002).
The ATD challenge we used in the current study (neurotransmitter challenge combined with
psychological negative mood induction) may also have acted as a stressor by perturbing brain
neuroregulatory and psychological coping systems thereby provoking emotional discomfort,
particularly in populations prone to depression (Spring et al., 2007). Data from human
experiments show that undergoing a stressor increases the reward value of palatable treat foods
(Spring et al., 2003). Dallman and colleagues (M. F. Dallman et al., 2004; Pecoraro, Reyes,
Gomez, Bhargava, & Dallman, 2004) posit that preference for high energy “comfort foods”
following stress has evolved to replenish the energy stores depleted by physiological and
behavioral coping responses. Nonhuman data show increased intake of sweet and fatty foods
after various stressors (M. F. Dallman et al., 2004; Dess, Choe, & Minor, 1998), as well as an
association with abdominal obesity (M.F. Dallman, Pecoraro, & la Fleur, 2005). Our finding
that ATD increased overweight participants’ consumption of calories from sweets suggests a
need to elucidate common neurobiological mechanisms whereby ATD and other stressors
promote increased consumption of sweets leading to overweight and obesity.
This study has several limitations. First, the range of BMI was restricted by exclusion criteria.
Differences between the lean and overweight groups might have been greater if more obese
individuals (BMI ≥ 35) had participated in the study. Those with class II or greater obesity
were excluded because it remains unclear whether the amino acid dosages used in the present
ATD protocol are effective in more obese individuals. In addition, self-reported measures of
height and weight were used instead of more objective measures. Second, carbohydrate-rich
foods were not purely carbohydrate in composition and protein-rich foods were not purely
protein, because single nutrient foods rare in nature or in a typical diet. Carbohydrate-rich foods
were chosen to be have at least a >6:1 carbohydrate to protein because such foods have
insufficient protein to block the insulin-mediated rise in plasma tryptophan after carbohydrate
intake (Yokogoshi & Wurtman, 1986). Illustrativecarbohydrate-rich menu items included
potato chips, spaghetti, and M&M candies. Illustrative protein-rich foods were baked chicken,
cheese, and roasted nuts. A third limitation is that the first food consumed might not have
necessarily been the most immediately desired food. This assumption was based on findings
that palatable food cues trigger activation of brain regions that enhance preferences for
immediate over delayed rewards (Hariri et al., 2006; Kelley, Schlitz, & Landry, 2005; McClure,
Ericson, Laibson, Lowenstein, & Cohen, 2007; McClure, Laibson, Loewenstein, & Cohen,
2004; Tanaka et al., 2004), however other factors could have guided the first food consumed.
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Finally, the sample size was estimated based on the hypotheses of the parent study. The number
of participants tested may, therefore, may have been insufficient to detect differences in food
consumption across conditions, given that previously observed effects of ATD on food intake
have been modest (Oldman et al., 1995). On the other hand, however, some studies using much
smaller sample sizes (N=20) did detect effects of ATD on food intake in recovered bulimics
(e.g., (Weltzin et al., 1995)). The present study was an initial exploration into the effect of ATD
on food intake in a non-eating disordered population, larger studies are merited to further
explore this effect which will help elucidate the role of serotonin in “comfort eating.”
In conclusion, the present study provides evidence of serotonergic involvement in the food
consumption of overweight individuals. Acutely lowering serotonin synthesis by tryptophan
depletion heightened the intake of sweet-tasting foods by overweight individuals, regardless
of gender, smoking status, history of MDD, or level of depressive symptoms. Whether
tryptophan depletion enhanced the incentive salience of the rewarding food (Robinson &
Berridge, 1993, 2000) or interfered with the ability to modulate food intake warrants further
investigation.
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Figure 1.
Difference in sweet and non-sweet calorie intake between placebo and ATD
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Figure 2.
Change in number of participants making sweet and non-sweet first choices from placebo to
ATD2
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Table 1
Timeline of experimental session
Time Procedure
8:00 a.m. Baseline testing of depressive symptoms (M-HAMD) and plasma amino acid levels
8:30 a.m. Standardized breakfast (puffed rice, peaches, nondairy creamer, gelatin, and sugar)
9:30 a.m. Consumption of amino acid or placebo mixture
10:30 a.m. Four low-protein cookies and Kool-aid
12:30 p.m. Lunch (graham crackers, cream cheese, boiled potatoes and butter, green beans, gelatin)
1:30 p.m. All reading materials removed from observation room
2:30 p.m. Following the guided imagery procedure, the M-HAMD assessment and blood sampling for amino acid levels was
repeated
3:00 p.m. Snack (4 low-protein cookies and Kool-aid)
5:30 p.m. Dinner test meal
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Table 2
Sample Foods Classified as Carbohydrate- or Protein-Rich and Sweet or Non-Sweet
Carbohydrate Protein
Sweet M&Ms Cheesecake
Applesauce Sweet and sour chicken
Crumb cake Choc. covered peanuts
Gummy bears Honey glazed ham
Chocolate chip cookies Chocolate pudding
Non-sweet Mashed potatoes Peanuts
Popcorn Cheese pizza
French fries String cheese
Stir fried vegetables Ham & cheese sandwich
Spaghetti w/marinara Spaghetti w/meatballs
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Table 3
Demographic characteristics of participants.
Lean (n=36) Overweight (n=19)
Age 32.51 (11.52) 34.21 (9.39)
Gender
 (% female) 64% 42%
Ethnicity (%)
 Caucasian 61% 58%
 African American 22% 32%
 Hispanic 6% 0%
 Asian 9% 5%
 Missing 2% 0%
Smokers 58% 58%
Depression History 44% 47%
Notes. Values in parentheses are standard deviations.
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Table 4
Total, carbohydrate, protein, sweet and non-sweet caloric intake of participants in
each condition.
Lean (n=36) Overweight (n=19)
Total
 Placebo 882.38 (492.24) 1041.43 (681.57)
 ATD 886.26 (328.83) 1148.99 (738.54)
Carbohydrate
 Placebo 290.68 (214.18) 353.94 (245.92)
 ATD 307.98 (203.16) 371.28 (277.20)
Protein
 Placebo 591.41 (448.35) 687.49 (611.02)
 ATD 578.27 (305.13) 777.71 (773.82)
Sweet
 Placebo 266.76 (202.85) 254.74 (256.19)
 ATD 234.10 (133.97) 345.33 (286.95)
Non-sweet
 Placebo 615.33 (395.77) 786.69 (563.64)
 ATD 652.15 (301.87) 803.66 (561.62)
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